This is a phase Ⅳ follow-up clinical trial based on the previous Phase Ⅳ clinical trial of an inactivated COVID-19 vaccine (CoronaVac) manufactured by Sinovac Life Sciences Co., Ltd.The purpose of this study is to evaluate the immunogenicity,safety and cross-immune response of booster immunization using COVID-19 vaccine,to compare the similarities and differences of immune responses between primary immunization and booster immunization and to detect antibody against hepatitis A and evaluate the immune persistence of the one dose immunization schedule of hepatitis A vaccine in healthy population aged 18 years and older.
This study is a phase 4 clinical trial to evaluate the immunogenicity,safety and cross-immune
response of booster immunization using COVID-19 vaccine，to compare the similarities and
differences of immune responses between primary immunization and booster immunization and to
detect antibody against hepatitis A and evaluate the immune persistence of the one dose
immunization schedule of hepatitis A vaccine in healthy population aged 18 years and older.
The experimental vaccine is manufactured by Sinovac Life Sciences Co., Ltd.. A total of 180
healthy subjects received two dose of inactivated COVID-19 vaccine (CoronaVac) based on
primary immunization in previous Phase Ⅳ clinical trial will be enrolled, including 90 adults
aged 18-59 years and 90 elderly elderly aged 60 years and older.Subjects in each age group
will receive the booster immunization of CoronaVac(the third dose) and will be collected
blood sample before booster immunization and 14 days after booster immunization.
Biological: Inactivated COVID-19 Vaccine
600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
Other Name: CoronaVac
Inclusion Criteria:
- Participated in the clinical studies on the safety and immunogenicity of Inactivated
COVID-19 Vaccine combined immunization with 23-valent pneumococcal polysaccharide
vaccine in Rushan city, Shandong Province from July to October 2021;
- The interval between complete immunization with two doses of COVID-19 vaccine is 6-8
months;
- Subjects will be willing to participate in the study and follow the study procedure to
collect venous blood;
- Proven legal identity;
Exclusion Criteria:
- History of asthma, history of allergy to the vaccine or vaccine components,or serious
adverse reactions to the vaccine, such as urticaria, dyspnea,and angioedema;
- Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;
- Fever at the time of vaccination, or acute onset of chronic disease, or uncontrolled
severe chronic disease, or acute disease;
- Pregnancy or lactation;
- Receipt of attenuated live vaccines in the past 14 days;
- Receipt of inactivated or subunit vaccines in the past 7 days
- According to the investigator's judgment, the subject has any other factors that are
not suitable for participating in the clinical trial.
Rushan City Center for Disease Control and Prevention
Weihai, Shandong, China
Li Zhang, Master, Principal Investigator
Shandong Provincial Center for Disease Control and Prevention